Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 10/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 7/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 5/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 5/20 | 1.00 |
| ▸ | CCND3 | P30281 | 4/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL31702788 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665748 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29777523 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL291157 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290572 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665749 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL23683025 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL663219 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29387962 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290347 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2021-09-09 | — | — | US | disclosed |
| US-10245248-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2017-05-04 | — | — | US | disclosed |
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2017-05-04 | — | — | US | disclosed |
| WO-2015192123-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CDK4 763/4885CDK1 2936/4885CDK9 2380/4885 |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CDK4 763/4885CDK1 2936/4885CDK9 2380/4885 |
| US-10245248-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, FAH | CDK4 1134/4885CDK1 2992/4885CDK9 2232/4885 |
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, FAH | CDK4 1134/4885CDK1 2992/4885CDK9 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.